<DOC>
	<DOC>NCT00667823</DOC>
	<brief_summary>The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.</brief_summary>
	<brief_title>Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Signed informed consent prior to initiation of any studymandated procedure. Patients with pulmonary arterial hypertension and having completed the eventdriven study, AC 055 302/SERAPHIN, or Patients who have experienced a clinical worsening of PAH in AC 055 302/SERAPHIN and for whom a written approval to roll over into this study has been obtained from the Sponsor. Women of childbearing potential must have a negative pretreatment serum pregnancy test and must use a reliable method of contraception during study treatment and for at least 28 days after study treatment termination. Any major violation of protocol AC 055 302/SERAPHIN. Pregnancy or breastfeeding. AST and/or ALT &gt; 3 times the upper limit of the normal range. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease. Known hypersensitivity to ACT 064992 or any of the excipients.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SERAPHIN</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>ACT-064992</keyword>
</DOC>